Company Overview and News

 
Indo Rama Synthetics (India) Limited - Allotment of Securities

2018-08-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Check out Insider Trading transaction for August 1, 2018; JSW Steel, Kotak Mahindra Bank in focus

2018-08-04 moneycontrol
Madhav Marbles & Granites Ltd.: Riddhima Doshi bought 31,478 shares through market purchase on August 1, 2018
532400 KPIT KMBKY 512529 500228 IDRNF 500207 KOTAKBANK 500247 SEQUENT JSWSTEEL INDORAMA

 
Indo Rama Synthetics (India) Limited - Shareholders meeting

2018-07-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Indo Rama Synthetics (India) Limited - Shareholders meeting

2018-07-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Indo Rama Synthetics (India) Limited - Corrigendum

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Indo Rama Synthetics (India) Limited - Disclosure under SEBI Takeover Regulations

2018-07-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Indo Rama Synthetics (India) Limited - Allotment of Securities

2018-07-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Indo Rama Synthetics (India) Limited - Reply to Clarification Sought

2018-07-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Indo Rama Synthetics (India) Limited - Shareholders meeting

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

 
Indo Rama Synthetics (India) Limited - Clarification

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

27
Nifty closes Day 1 of July series above 10,700, Sensex zooms 386 points on global cues

2018-06-29 moneycontrol
Market Update: The market reversed Thursday's losses and ended the first day of July series on a strong note, backed by positive global cues. All sectoral indices ended in the green with FMCG and Metal leading the charge with 2-3 percent gains.
500325 IDRNF 500207 RELIANCE IDBI 532712 532733 5225 RCOM RIGD IHHHF SUNTV RLNIY SBAZ YESBANK 500116 IBN 532648 YYBKY 532843 ICICIBANK FORTIS 532174 SNQVY Q0F INDORAMA

27
Market Live: Nifty reclaims 10,700, Sensex jumps 350 pts; rupee recovers sharply

2018-06-29 moneycontrol
Buzzing: Shares of IDBI Bank gained 12 percent as company clarified about LIC planning to inject Rs 13,000 crore in the company.
500325 IDRNF 500207 RELIANCE IDBI 532712 532733 5225 RCOM RIGD IHHHF SUNTV RLNIY SBAZ YESBANK 500116 IBN 532648 YYBKY 532843 ICICIBANK FORTIS 532174 SNQVY Q0F INDORAMA

38
Market Live: Nifty at day#39;s high, Sensex jumps 300 pts; Europe trades strong

2018-06-29 moneycontrol
The rupee has been one of the worst performing currencies among peers. Against the USD, it has depreciated by 6.6 percent in calendar year 2018 and 8 percent, Year to Date (YTD). Adding to our concern is the increasingly hawkish Federal Reserve, which has now initiated a reversal of the Quantitative Easing (QE) – marking an end to global easy money.
BAJAJ-AUTO INDIANB 500325 IDRNF 500207 TCHQY 532712 532755 534976 5225 RCOM TORNTPOWER 522287 LHFLY 500570 500253 SUNTV RLNIY SBAZ BANG GRAPHITE 532946 JSWSTEEL TECHM TATASTEEL FORTIS TATLY LICHSGFIN Q0F 500228 RELIANCE 532814 532779 532977 532733 500470 RIGD IHHHF TATAMOTORS 509488 INDIGO HINDALCO IBN 532843 539448 HNDNF VMART ICICIBANK TTST 532174 KALPATPOWR SNQVY 500440 INDORAMA TTM

 
Indo Rama Synthetics (India) Limited - Updates

2018-06-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IDRNF 500207 INDORAMA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...